Eosinophilic Esophagitis - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2017, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 4 and 4 respectively.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Eosinophilic Esophagitis - Overview 6
Eosinophilic Esophagitis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 9
Eosinophilic Esophagitis - Therapeutics Assessment 10
Assessment by Target 10
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 18
Adare Pharmaceuticals Inc 18
Calypso Biotech SA 18
Celgene Corp 19
DBV Technologies SA 19
Dr. Falk Pharma GmbH 20
Quorum Innovations LLC 20
Regeneron Pharmaceuticals Inc 21
Shire Plc 21
Eosinophilic Esophagitis - Drug Profiles 22
BPRX-060216 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
budesonide - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
budesonide - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CALY-002 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
dupilumab - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
fluticasone propionate - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
fluticasone propionate - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Qi-201 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
RPC-4046 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Viaskin Milk - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Eosinophilic Esophagitis - Dormant Projects 49
Eosinophilic Esophagitis - Product Development Milestones 50
Featured News & Press Releases 50
Feb 03, 2017: DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis 50
Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses 50
Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy 51
Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions 51
Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis 52
Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children 52
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 53
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 53
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 54
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 55
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis 55
May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 56
May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis 57
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60

List of Tables

Number of Products under Development for Eosinophilic Esophagitis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Products under Development by Companies, H2 2017 9
Number of Products by Stage and Target, H2 2017 11
Number of Products by Stage and Mechanism of Action, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals Inc, H2 2017 18
Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H2 2017 18
Eosinophilic Esophagitis - Pipeline by Celgene Corp, H2 2017 19
Eosinophilic Esophagitis - Pipeline by DBV Technologies SA, H2 2017 19
Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2017 20
Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H2 2017 20
Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 21
Eosinophilic Esophagitis - Pipeline by Shire Plc, H2 2017 21
Eosinophilic Esophagitis - Dormant Projects, H2 2017 49